Global Acromegaly Drug Market, By Drug Class (Growth Hormone Receptor Antagonists, Dopamine Agonists, Recombinant Human IGF-1, Somatostatin Analogs), Type (Octreotide, Pasireotide, Lanreotide, Pegvisomant), Application (Hospital, Pharmacy, Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
The acromegaly drug market is expected to gain growth at a potential rate of 5.60% in the forecast period of 2021 to 2028. The high rate of hormonal diseases incidences across the globe is the factor responsible for the market growth.
Acromegaly is a type of a rare hormonal disorder which is also known as gigantism. It generally occurs when pituitary gland releases extreme growth hormone in the body because of the tumor formation in the pituitary gland. This irregular production of growth hormone results in the bone enlargement. It largely affects the geriatric population.
The rapid increase in prevalence of acromegaly is expected to accelerate the market growth in the forecast period of 2021 to 2028. Likewise, the rapid change in the lifestyle of the people across the globe and rise in of genetic diseases amongst people are also predictable to enhance the acromegaly drug market growth. Furthermore, the rapid rise in the rate of hormonal diseases, endocrine diseases and hypopituitarism is also projected to drive the market growth rate. Also, the ongoing clinical trials being carried out by many pharmaceuticals companies and strong government support for research and development are also expected to influence the acromegaly drug market growth globally.
In addition, the presence of strong pipeline and the increase in the popularity of drugs over surgeries are likely to create various new opportunities that will impact this acromegaly drug market growth in the forecast period of 2021 to 2028.
However, the dearth of awareness of the people about the genetic and hormonal disorder and difficulty in diagnosis are expected to act as major restraints towards the growth of the acromegaly drug market, whereas the Strict government policies and a medical scheme such as providing subsidized drugs and reimbursement in the developing countries can challenge the growth of the target market in the above mentioned forecast period.
This acromegaly drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis on the acromegaly drug market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Acromegaly Drug Market Scope and Market Size
The acromegaly drug market is segmented on the basis of drug class, type and application. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- Based on drug class, the acromegaly drug market is segmented into growth hormone receptor antagonists, dopamine agonists, recombinant human IGF-1 and somatostatin analogs.
- On the basis of type, the acromegaly drug market is segmented into octreotide, pasireotide, lanreotide and pegvisomant.
- The acromegaly drug market is also segmented on the basis of application into hospital, pharmacy, clinics and others.
Acromegaly Drug Market Country Level Analysis
The acromegaly drug market is analyzed and market size information is provided by country by, drug class, type and application as referenced above.
The countries covered in the acromegaly drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the acromegaly drug market due to high healthcare expenditure, rise in government support for research and development and the strong presence of some of the leading players. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the rapid increase in the population, rise in the prevalence of hormonal diseases and rapid development of the healthcare sector.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Apart from the above, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The acromegaly drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Acromegaly Drug Market Share Analysis
The acromegaly drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to acromegaly drug market.
The major players covered in the acromegaly drug market report are Novartis AG, Mylan N.V., Ipsen Pharma, Pfizer Inc., Fresenius Kabi USA, Zydus Pharmaceuticals Inc., Par Pharmaceuticals, Hikma Pharmaceuticals PLC, Teva Pharmaceuticals USA, Inc., Peptron, Chiasma, Inc., Ingenus Pharmaceuticals, LLC, Recordati Rare Diseases, F. Hoffmann-La Roche Ltd., Crinetics Pharmaceuticals, Inc., Foresee Pharmaceuticals Co., Ltd, Sun Pharmaceutical Industries Ltd., Amryt Pharma plc, Johnson & Johnson Services, Inc, and Sagent Pharmaceuticals, Inc., among other domestic and global players. Acromegaly drug market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.